Wave Life Sciences (WVE)
NASDAQ:WVE
Want to see WVE full AI Analyst Report?
Top Page
Wave Life Sciences
(NASDAQ:WVE)
Select Model
Select Model
Rating:55Neutral
Price Target:
$7.50
▲(0.13% Upside)
Action:ReiteratedDate:04/29/26
The score is held back primarily by weak financial performance (large ongoing losses and significant cash burn) and soft technicals (below key moving averages with negative MACD). Offsetting these, the latest earnings call reflected strong operational momentum and a long cash runway supporting multiple upcoming clinical/regulatory catalysts.
Positive Factors
Strong cash runway
A cash balance of $544.6M funding into Q3 2028 materially reduces near‑term financing pressure, allowing Wave to advance multiple clinical programs to key inflection points (Phase IIa starts and regulatory interactions) without immediate dilution, improving execution optionality over the next 2–3 years.
Negative Factors
Persistent high cash burn
Sustained negative operating and free cash flow near ~$180M TTM signals ongoing reliance on external financing or milestone receipts to fund R&D. Over a multi‑quarter horizon this raises dilution risk, pressures capital allocation decisions, and limits flexibility to expand programs or commercial investments without securing additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash runway
A cash balance of $544.6M funding into Q3 2028 materially reduces near‑term financing pressure, allowing Wave to advance multiple clinical programs to key inflection points (Phase IIa starts and regulatory interactions) without immediate dilution, improving execution optionality over the next 2–3 years.
Read all positive factors
Wave Life Sciences (WVE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.41B
Dividend YieldN/A
Average Volume (3M)5.41M
Price to Earnings (P/E)―
Beta (1Y)2.04
Revenue Growth-31.58%
EPS Growth-27.41%
CountryUS
Employees287
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.06
Shares Outstanding192,379,970
10 Day Avg. Volume3,369,866
30 Day Avg. Volume5,408,598
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)5.45
Price to Sales (P/S)67.10
P/FCF Ratio-15.29
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue12.65
Enterprise Value/Gross Profit13.49
Enterprise Value/Ebitda-4.99
Forecast
1Y Price Target
$24.40Price Target Upside225.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$55.94M
Wave Life Sciences Business Overview & Revenue Model
Company Description
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic ac...
How the Company Makes Money
Wave Life Sciences has historically generated little to no recurring product revenue because its medicines are largely in clinical development rather than commercialized. The company primarily funds operations through a combination of (1) collabor...
Wave Life Sciences Earnings Call Summary
Earnings Call Date:Apr 28, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Positive
The call conveyed substantial positive momentum: meaningful revenue growth (largely license-related), improved net loss, strong cash runway, and multiple encouraging clinical readouts and development milestones (notably WVE-007 visceral fat and VMR improvements, advancing WVE-007 into Phase IIa, and WVE-006 demonstrating therapeutically relevant MAAT and regulatory path potential). Headwinds include rising operating expenses, remaining net losses, regulatory and competitive uncertainties, and the need for careful patient enrichment for 007 trials. On balance, the operational and clinical progress and capitalization materially outweigh the listed challenges, but execution risk and competitive dynamics remain important near-term considerations.Positive Updates
Strong Revenue Growth
Q1 2026 revenue of $38.2M versus $9.2M in Q1 2025, a ~315% year-over-year increase driven primarily by recognizing the full amount of revenue associated with regaining full rights to WVE-006 and progress in the GSK collaboration.
Negative Updates
Increased Operating Expenses
R&D expenses rose to $47.4M in Q1 2026 from $40.6M in Q1 2025 (a ~16.7% increase). G&A expenses rose to $22.1M from $18.4M (a ~20.1% increase), reflecting increased investment to advance clinical programs and support pipeline expansion.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth
Q1 2026 revenue of $38.2M versus $9.2M in Q1 2025, a ~315% year-over-year increase driven primarily by recognizing the full amount of revenue associated with regaining full rights to WVE-006 and progress in the GSK collaboration.
Read all positive updates
Company Guidance
On the call Wave provided concrete operational and clinical guidance and several key metrics: financials for Q1 2026 included $38.2M revenue, R&D expense $47.4M, G&A $22.1M, net loss $26.1M, and $544.6M cash expected to fund operations into Q3 2028; clinically, Wave plans to initiate the Phase IIa multiple‑dose portion of INLIGHT this quarter (Q2 2026) and to start INHBE combination and post‑incretin maintenance studies later in 2026; the Phase IIa is a global, placebo‑controlled trial enrolling BMI 35–50 patients with and without T2D across two doses (240 mg and 400 mg) in four cohorts of 40 patients each (160 total), with dosing on Day 1 and Day 85 and a 12‑month follow‑up (first main assessment at Day 85); Phase I 240 mg data show durable knockdown through ≥7 months with placebo‑adjusted visceral fat −14.3%, total fat −5.3%, waist circumference −3.3% and a VMR improvement of ~16.5% (vs semaglutide 12.2% and vimanrimab 18.8%); for RNA editing, WVE‑006 interim data demonstrated restoration of functional MAAT (including >20 μM AAT during an acute phase response) with 200 mg biweekly, Wave will present 400 mg monthly and single‑dose 600 mg data at ATS/May 18 and expects regulatory feedback on a potential accelerated approval pathway mid‑2026, and WVE‑008 is on track for a 2026 CTA submission.Wave Life Sciences Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.80M | 42.73M | 108.30M | 113.31M | 3.65M | 40.96M |
| Gross Profit | 67.34M | 33.88M | 108.30M | 113.31M | 3.65M | 40.96M |
| EBITDA | -182.09M | -195.53M | -101.74M | -58.79M | -152.61M | -117.18M |
| Net Income | -183.59M | -204.38M | -97.01M | -57.51M | -161.82M | -122.25M |
Balance Sheet | ||||||
| Total Assets | 583.54M | 638.50M | 352.21M | 274.95M | 146.39M | 207.01M |
| Cash, Cash Equivalents and Short-Term Investments | 544.59M | 602.07M | 302.08M | 200.35M | 88.50M | 150.56M |
| Total Debt | 15.71M | 17.77M | 25.40M | 32.12M | 37.61M | 29.92M |
| Total Liabilities | 71.81M | 112.27M | 142.69M | 235.32M | 191.48M | 174.51M |
| Stockholders Equity | 511.73M | 526.23M | 209.51M | 39.63M | -45.09M | 32.50M |
Cash Flow | ||||||
| Free Cash Flow | -183.34M | -187.49M | -151.96M | -20.55M | -129.14M | -89.55M |
| Operating Cash Flow | -182.35M | -187.49M | -151.03M | -19.43M | -127.78M | -88.99M |
| Investing Cash Flow | -981.99K | -718.00K | -938.00K | -1.11M | -1.25M | -560.00K |
| Financing Cash Flow | 489.54M | 488.24M | 253.89M | 132.53M | 67.19M | 55.83M |
Wave Life Sciences Technical Analysis
Negative
7.49
Price Trends
11.20
Negative
12.53
Negative
10.22
Negative
Market Momentum
-1.21
Negative
35.55
Neutral
71.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WVE, the sentiment is Negative. The current price of 7.49 is below the 20-day moving average (MA) of 8.03, below the 50-day MA of 11.20, and below the 200-day MA of 10.22, indicating a bearish trend. The MACD of -1.21 indicates Negative momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 71.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WVE.
Wave Life Sciences Risk Analysis
Wave Life Sciences disclosed 72 risk factors in its most recent earnings report. Wave Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Wave Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $1.62B | -12.79 | -28.85% | ― | ― | -33.82% | |
58 Neutral | $2.06B | -273.00 | -2.05% | ― | 404.50% | 94.17% | |
55 Neutral | $1.41B | -13.91 | -56.41% | ― | -31.58% | -27.41% | |
52 Neutral | $980.50M | -5.55 | -38.79% | ― | ― | 17.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.44B | -13.92 | -8396.72% | ― | 146.73% | -190.09% | |
50 Neutral | $1.56B | -14.96 | -57.48% | ― | 698.96% | 73.41% |
* Healthcare Sector Average
WVE
Wave Life Sciences
7.32
-0.41
-5.30%
PGEN
Precigen
4.08
2.56
168.42%
STOK
Stoke Therapeutics
33.08
23.38
241.03%
ORIC
Oric Pharmaceuticals
9.77
4.07
71.40%
NUVB
Nuvation Bio
4.49
2.11
88.66%
RAPP
Rapport Therapeutics, Inc.
33.89
22.91
208.65%
Wave Life Sciences Corporate Events
Business Operations and StrategyFinancial Disclosures
Wave Life Sciences Reports Q1 Results, Advances RNA Pipeline
Positive
Apr 28, 2026
On April 28, 2026, Wave Life Sciences reported first quarter 2026 results and highlighted progress across its RNA-based pipeline, led by obesity candidate WVE-007 and AATD therapy WVE-006. The company ended March 31, 2026 with $544.6 million in ca...
Business Operations and StrategyShareholder Meetings
Wave Life Sciences Plans Redomiciling From Singapore to U.S.
Neutral
Apr 21, 2026
On April 21, 2026, Wave Life Sciences announced that it is advancing plans to redomicile its parent company from Singapore to the United States through a court-approved scheme of arrangement under Singapore’s Companies Act. The biotechnology...
Business Operations and Strategy
Wave Life Sciences Plans Redomiciling to Delaware Corporation
Positive
Apr 15, 2026
On April 15, 2026, Wave Life Sciences announced plans to restructure its corporate group by redomiciling its parent company from Singapore to the United States through the creation of a new Delaware corporation. The boards of Wave Life Sciences Lt...
Business Operations and StrategyProduct-Related Announcements
Wave Life Sciences Reports Positive WVE-007 Obesity Trial Data
Positive
Mar 26, 2026
On March 26, 2026, Wave Life Sciences reported positive interim Phase 1 data from its first-in-human INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA, in otherwise healthy individuals with overweight or obesity. A single 240 mg dose...
Business Operations and StrategyFinancial Disclosures
Wave Life Sciences Highlights 2025 Results and Obesity Progress
Positive
Feb 26, 2026
On February 26, 2026, Wave Life Sciences reported fourth-quarter and full-year 2025 results, highlighting progress across its RNA-based pipeline and a strong cash position of $602.1 million as of December 31, 2025, providing runway into the third ...
Business Operations and StrategyProduct-Related Announcements
Wave Life Sciences Regains WVE-006 Rights, Plans Accelerated Path
Positive
Feb 2, 2026
On February 2, 2026, Wave Life Sciences announced that it has regained full rights to WVE-006, its first-in-class GalNAc-conjugated RNA editing candidate for alpha-1 antitrypsin deficiency (AATD), from partner GSK, enabling the company to accelera...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.